GlycoMimetics board members possess a broad and deep range of experience in varied business, financial, scientific, medical and multinational sectors of the life sciences. Our Board works closely with our Management Team to drive the success of our programs.
- M. James Barrett, Ph.D., Chairman of the Board of Directors
- John J. Baldwin, Ph.D., Director
- William Gust, Director
- Michael Henos, Director
- Rachel K. King, Chief Executive Officer
- John Magnani, Ph.D., Vice President and Chief Scientific Officer
- Franklin H. Top, Jr., M.D., Director
M. James Barrett, Ph.D., Chairman of the Board of Directors
Dr. Barrett joined venture capital firm New Enterprise Associates (NEA), GlycoMimetics, Inc.’s lead investor, in 2001 as a General Partner. He specializes in biotechnology and works with members of NEA’s healthcare investment group on medical devices and specialty pharmaceutical companies. Present board memberships in addition to GlycoMimetics include Amicus Therapeutics, Cardioxyl Pharmaceuticals, Clovis Oncology, PhaseBio Pharmaceuticals, Predictive Biosciences, Psyadon Pharmaceuticals, Roka Bioscience, Sensors for Medicine and Science, Inc., Supernus Pharmaceuticals, Inc., Targacept, Inc. and Zosano Pharma, Inc. Dr. Barrett formerly served on the boards of CoGenesys (acquired by Teva Pharmaceutical Industries), Iomai Corporation (acquired by Intercell AG), MedImmune, Inc. (acquired by AstraZeneca) and Pharmion (acquired by Celgene). Prior to NEA, Dr. Barrett served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 – 2001). Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 – 1995), President and CEO of Life Technologies (1985 – 1987), and President and CEO of Bethesda Research Labs (1982 – 1983). Prior to 1982, Dr. Barrett worked in various divisions of SmithKline. Dr. Barrett received a Ph.D. in Biochemistry at the University of Tennessee, his M.B.A. from the University of Santa Clara, and a B.S. in Chemistry from Boston College.
John J. Baldwin, Ph.D., Director
Dr. Baldwin co-founded Hua Medicine in 2010 and is a member of the Board of Directors. In 2001 he co-founded Vitae Pharamaceuticals, Inc. where he served as the company’s President and Chief Scientific Officer. Prior to that, he spent nine years at Pharmacopeia, Inc., where he was a co-founder and served as Chief Scientific and Technology Officer. During this period, he co-founded WuXi PharmaTech, a research and development service company located in China, and served on its Board of Directors. Prior to Pharmacopeia, Dr. Baldwin was a Distinguished Senior Scientist at Merck & Co., where he spent 33 years in various scientific and management positions.
William Gust, Director
Mr. Gust is President & CEO and Co-Founder of Plasmonix, Inc., an early-stage nano-materials company serving the life science industry. Prior to launching Plamonix, he served as Managing General Partner for Anthem Capital Management. He has more than 30 years of venture capital experience nurturing and supporting start-up companies such as BioRexis, Immunicon, HealthSouth Rehabilitation, Sensors for Medicine & Science, Apple Computer, Chucky Cheese, and Sequoia Software, in addition to GlycoMimetics. He has a wealth of experience in technology transfer and has worked closely with a number of academic research institutions including Johns Hopkins and the University of Maryland. Prior to his venture capital career, Mr. Gust was with First Boston and L.F. Rothschild in security analysis and investment banking.
Michael Henos, Director
Mr. Henos is the founder and Managing General Partner of Alliance Technology Ventures, L.P. (“ATV”), a venture capital firm based in the Southeast. Prior to founding ATV in 1993, Mr. Henos served as a General Partner of Aspen Ventures, a venture capital fund, and as a Vice President with 3i Ventures, the predecessor fund to Aspen during the period from 1986 to 1993. Mr. Henos has extensive experience as a venture capital investor and as a current and past director of various public and privately held biopharmaceutical companies. He more recently has served as a director of Genoptix, Inc., Atherogenics, Inc., and Inhibitex, Inc., all publicly held biopharmaceutical companies. Mr. Henos was Chairman of the Board for both Atherogenics and Inhibitex and also served as their compensation committee chairs. Prior to venture capital investing, Mr. Henos held operating positions with Science Applications Inc, Revlon Healthcare Group and Pro-med Technologies, which he co-founded. Mr. Henos received a B.S. in Economics and a M.B.A. in Finance from the University of California, Los Angeles.
Franklin H. Top, Jr., M.D., Director
Dr. Top joined MedImmune in June 1988 as Executive Vice President and was a member of its Board of Directors from 1988 through 2004. He became MedImmune’s Medical Director in 1990. From 2004 to 2010, Dr. Top served as Senior Vice President in MedImmune, LLC’s venture capital affiliate, MedImmune Ventures Inc. From 1987 to 1988, Dr. Top served as Senior Vice President for Clinical and Regulatory Affairs at Praxis Biologics. Prior to 1987, Dr. Top served for 22 years in the U.S. Army Medical Research and Development Command, where he was appointed Director and Commandant, Walter Reed Army Institute of Research in 1983.